Cargando…
Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment
Coronavirus Disease 2019 (COVID-19) pandemic has been on the agenda of humanity for more than 2 years. In the meantime, the pandemic has caused economic shutdowns, halt of daily lives and global mobility, overcrowding of the healthcare systems, panic, and worse, more than 6 million deaths. Today, th...
Autores principales: | Sahin, Gokben, Akbal-Dagistan, Ozlem, Culha, Meltem, Erturk, Aybige, Basarir, Nur Sena, Sancar, Serap, Yildiz-Pekoz, Ayca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Pharmacists Association. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181835/ https://www.ncbi.nlm.nih.gov/pubmed/35691607 http://dx.doi.org/10.1016/j.xphs.2022.06.004 |
Ejemplares similares
-
Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis
por: Yildiz Pekoz, Ayca, et al.
Publicado: (2022) -
Pulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effects
por: Akbal-Dagistan, Ozlem, et al.
Publicado: (2022) -
Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
por: Erelel, Mustafa, et al.
Publicado: (2021) -
A Novel Semi-Solid Self-Emulsifying Formulation of Aprepitant for Oral Delivery: An In Vitro Evaluation
por: Nazlı, Hakan, et al.
Publicado: (2023) -
Advances in Pulmonary Drug Delivery
por: Yıldız-Peköz, Ayca, et al.
Publicado: (2020)